Shots:

• The P-III SAkuraSky study involves assessing of satralizumab (120mg- SC) + baseline immunosuppressant therapy vs PBO + baseline immunosuppressant therapy in ratio (1:1) in 83 patients with NMOSD
• P-III study results: relapse-free patients @ 48- 96 and 144wks. (89%- 78%- 74% vs 66%- 59%- 49%)- Experienced PDR (20% vs 43%); AQP4-IgG seropositive & seronegative subgroup: experienced a PDR (11% vs 43%) & (36% vs 43%)
• Satralizumab is a mAb targeting IL-6 receptor and has received Orphan Drug Designation in the US- EU- and Japan plus granted BT designation by the US FDA in Dec 2018 for NMOSD

Click here to­ read full press release/ article

Ref: Roche | Image: Roche